Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.
Treatment has evolved from acute management over a short period of time to using far more precise and less toxic therapies over many years. The disease still remains fatal in a majority of patients, but the overall survival has transformed from 1 to 2 years to 3 to 6 years.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More